Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 0.92%.

  • Akebia Therapeutics' EBITDA Margin rose 544600.0% to 0.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.07%, marking a year-over-year decrease of 3190000.0%. This contributed to the annual value of 43.33% for FY2024, which is 4759200.0% up from last year.
  • Akebia Therapeutics' EBITDA Margin amounted to 0.92% in Q3 2025, which was up 544600.0% from 0.4% recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EBITDA Margin ranged from a high of 23.3% in Q2 2022 and a low of 156.94% during Q2 2021
  • Moreover, its 5-year median value for EBITDA Margin was 49.04% (2024), whereas its average is 56.44%.
  • Examining YoY changes over the last 5 years, Akebia Therapeutics' EBITDA Margin showed a top increase of 2775000bps in 2021 and a maximum decrease of -643800bps in 2021.
  • Akebia Therapeutics' EBITDA Margin (Quarter) stood at 121.13% in 2021, then soared by 91bps to 10.88% in 2022, then skyrocketed by 96bps to 0.48% in 2023, then tumbled by -10158bps to 49.04% in 2024, then skyrocketed by 102bps to 0.92% in 2025.
  • Its EBITDA Margin was 0.92% in Q3 2025, compared to 0.4% in Q2 2025 and 10.66% in Q1 2025.